17,261 trials
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response as Per Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v. 1.1)…
Adenocarcinoma of the Prostate · Stage II Prostate Cancer · Stage III Prostate Cancer
Primary: Efficacy as Assessed by Number of Patients With Changes Across Transcript Profiles by Microarray Analysis in Prostate Cancer Specimens, Specifically Those With Complete…
Neoplasms
Primary: Objective Tumour Response According to RECIST Criteria — 14.0 Percentage of participants
Spasmodic Dysphonia · Voice Tremor
Primary: Number of Participants Who Reported Positive Effects. — 17; 20 Participants
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
Cortisol Resistance · Negative Feedback · ACTH
Primary: Proportion of Suppressors After Dexamethasone — 0; 1 Participants — p=0.4872
Chemotherapy-induced Nausea and Vomiting
Primary: Maximum Concentration (Cmax) of Aprepitant in Participants 0 to <2 Years of Age — 3550 ng/mL
Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 Participants
Prostate Cancer Metastatic
Primary: Percentage of Participants With PSA Response — 39.7; 15.9; 55.6 percentage of participants
Dermatitis, Atopic
Primary: Percentage of Participants Who Have an Investigator Global Assessment (IGA) Score of Clear or Almost Clear (0 or 1) at Week 12 and a Minimum 2 Grade Improvement in IGA…
Multiple Myeloma, Neoplasms
Primary: Confirmed Best Overall Response Rate (BORR) — 37.1; 50.0; 0; 7.4 percentage of participants
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 100.0; 100.0 percentage of participants
Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 92.9; 96.2; 74.1; 100.0 percentage of participants
Prostate Cancer · Psychosocial Effects of Cancer and Its Treatment · Radiation Toxicity
Primary: Percentage of Patients With Reduction From Baseline to the One-year EPIC Bowel Domain Score That Exceeds 5 Points — 30.1; 28.0 percentage of participants — p=0.19
Pompe Disease
Primary: Safety Assessments of the rAAV1-CMV-GAA (Study Agent), Changes Post Study Agent Administration. — 40,031; 29,638; 5,509,882; 1,907,161 mU/mL